{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T22:02:27Z","timestamp":1780005747610,"version":"3.53.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["RS-2023-CC140196"],"award-info":[{"award-number":["RS-2023-CC140196"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100025390","name":"Korean Cancer Survivor Healthcare R and D Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100025390","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008746","name":"National Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008746","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003645","name":"National Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003645","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1136\/ijgc-2024-006111","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T23:30:15Z","timestamp":1729726215000},"page":"101869","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of survival outcomes and safety between early and late initiation of niraparib maintenance in newly diagnosed advanced epithelial ovarian cancer"],"prefix":"10.1016","volume":"36","author":[{"given":"Se Ik","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2754-2657","authenticated-orcid":false,"given":"Eun Taeg","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunjin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Weon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Yoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4746-5572","authenticated-orcid":false,"given":"Myong Cheol","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2024-006111_bib1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1136\/ijgc-2024-006111_bib2","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","article-title":"Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials","volume":"115","author":"du Bois","year":"2009","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2024-006111_bib3","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1016\/S1470-2045(22)00139-5","article-title":"Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup","volume":"23","author":"Vergote","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2024-006111_bib4","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2024-006111_bib5","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2024-006111_bib6","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1\/GOG 3004 Trial","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2024-006111_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.04.024","article-title":"Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA\/ENGOT-OV26\/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer","volume":"189","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2024-006111_bib8","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1001\/jamaoncol.2023.2283","article-title":"Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial","volume":"9","author":"Li","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1136\/ijgc-2024-006111_bib9","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-Update and clarification: From the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2024-006111_bib10","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0167-9473(98)00096-6","article-title":"An application of changepoint methods in studying the effect of age on survival in breast cancer","volume":"30","author":"Contal","year":"1999","journal-title":"Comput Stat Data Anal"},{"key":"10.1136\/ijgc-2024-006111_bib11","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/annonc\/mdv500","article-title":"Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology\/Gynecologic Oncology Group study","volume":"27","author":"Tewari","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2024-006111_bib12","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejca.2012.07.023","article-title":"Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: Analysis of prospective randomised phase III trials","volume":"49","author":"Mahner","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2024-006111_bib13","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ygyno.2006.01.035","article-title":"Influence of interval between primary surgery and chemotherapy on short-term survival of patients with advanced ovarian, tubal or peritoneal cancer","volume":"102","author":"Paulsen","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-006111_bib14","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ejso.2006.02.013","article-title":"The interval from surgery to chemotherapy in the treatment of advanced epithelial ovarian carcinoma","volume":"32","author":"Rosa","year":"2006","journal-title":"Eur J Surg Oncol"},{"key":"10.1136\/ijgc-2024-006111_bib15","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s11523-023-00999-x","article-title":"Efficacy and Safety of Niraparib as First- Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China","volume":"18","author":"Zhao","year":"2023","journal-title":"Target Oncol"},{"key":"10.1136\/ijgc-2024-006111_bib16","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ygyno.2022.04.012","article-title":"Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA\/ENGOT-OV26\/ GOG-3012 study","volume":"166","author":"O\u2019Cearbhaill","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-006111_bib17","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1200\/JCO.20.00799","article-title":"Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial","volume":"38","author":"DiSilvestro","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2024-006111_bib18","series-title":"IGCS 2022 Annual Meeting Abstracts","article-title":"EP300\/#876 impact of initiation timing of niraparib maintenance treatment in newly diagnosed advanced ovarian cancer","author":"Wang","year":"2022"},{"key":"10.1136\/ijgc-2024-006111_bib19","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.3802\/jgo.2024.35.e3","article-title":"Adherence of PARP inhibitor for frontline maintenance therapy in primary epithelial ovarian cancer: a cross-sectional survey","volume":"35","author":"Kim","year":"2024","journal-title":"J Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-006111_bib20","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ygyno.2021.08.025","article-title":"Adherence to PARP inhibitor therapy among women with ovarian cancer","volume":"163","author":"Moss","year":"2021","journal-title":"Gynecol Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25009880?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25009880?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2024-006111","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T21:18:58Z","timestamp":1780003138000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25009880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1048891X25009880"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2024-006111","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of survival outcomes and safety between early and late initiation of niraparib maintenance in newly diagnosed advanced epithelial ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2024-006111","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101869"}}